Research progress on the influencing factors of chemotherapy-related cognitive impairment in lung cancer patients_West China Medical Journal

Authors：

WU Xiucen ¹ ,  CHEN Guihua ² , LI Qin ¹ , TANG Huan ¹ , SHEN Huapeng ¹

1. Department of Respiratory Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P. R. China;
2. Department of Nursing, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P. R. China;

Corresponding?author：

CHEN Guihua, Email: 300278@hospital.cqmu.edu.cn

Keywords：

Lung cancer; chemotherapy-related cognitive impairment; influence factor

DOI：

10.7507/1002-0179.202408250

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Chemotherapy-related cognitive impairment (CRCI) is one of the treatment-related side effects in cancer patients, which can reduce patients’ participation in medical decision-making and treatment, seriously affecting their daily function and quality of life. This article reviews the definition, research status, and influencing factors of CRCI in lung cancer patients, in order to provide basis and ideas for the subsequent evaluation and management of CRCI in lung cancer patients, and promote the optimization and improvement of the overall rehabilitation process of lung cancer patients.

Citation： WU Xiucen, CHEN Guihua, LI Qin, TANG Huan, SHEN Huapeng. Research progress on the influencing factors of chemotherapy-related cognitive impairment in lung cancer patients. West China Medical Journal, 2025, 40(1): 142-146. doi: 10.7507/1002-0179.202408250 Copy

1.	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
2.	秦娜, 馬紅霞, 靳光付, 等. 肺癌流行病學研究年度進展 2022. 中華醫學雜志, 2023, 103(14): 1068-1073.
3.	Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv, 2009, 3(4): 223-232.
4.	Lv L, Mao S, Dong H, et al. Pathogenesis, assessments, and management of chemotherapy-related cognitive impairment (CRCI): an updated literature review. J Oncol, 2020, 2020: 3942439.
5.	Wefel JS, Kesler SR, Noll KR, et al. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin, 2015, 65(2): 123-138.
6.	Takemura N, Ho MH, Cheung DST, et al. Factors associated with perceived cognitive impairment in patients with advanced lung cancer: a cross-sectional analysis. Support Care Cancer, 2022, 30(11): 9607-9614.
7.	Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med, 1983, 34: 35-46.
8.	黃唐, 劉丹. 肺癌患者化學治療后認知功能損傷的機制及診療進展. 華西醫學, 2021, 36(2): 255-259.
9.	Simó M, Rifà-Ros X, Vaquero L, et al. Brain functional connectivity in lung cancer population: an exploratory study. Brain Imaging Behav. 2018 Apr;12(2): 369-382.
10.	Simó M, Root JC, Vaquero L, et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol, 2015, 10(1): 38-45.
11.	Országhová Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci, 2021, 8: 770413.
12.	van de Kamp HJ, Molder MT, Schulkes KJG, et al. Impact of lung cancer treatment on cognitive functioning. Clin Lung Cancer, 2020, 21(2): 114-126. e3.
13.	Prapa P, Papathanasiou IV, Bakalis V, et al. Quality of life and psychological distress of lung cancer patients undergoing chemotherapy. World J Oncol, 2021, 12(2/3): 61-66.
14.	Papadopoulos D, Kiagia M, Charpidou A, et al. Psychological correlates of sleep quality in lung cancer patients under chemotherapy: a single-center cross-sectional study. Psychooncology, 2019, 28(9): 1879-1886.
15.	Chan YN, Leak Bryant A, Conklin JL, et al. Systematic review of cognitive impairment in colorectal cancer survivors who received chemotherapy. Oncol Nurs Forum, 2021, 48(6): 634-647.
16.	周麗, 劉艷萍, 顏雯晶, 等. 肺癌化療患者的認知功能現狀及影響因素研究. 中國醫藥導報, 2020, 17(7): 86-89.
17.	李歡, 丁杏, 何惠敏, 等. 肺癌化療后神經認知功能損害的影響因素分析及其與生活質量的相關性研究. 臨床和實驗醫學雜志, 2021, 20(11): 1191-1195.
18.	王鳳, 王麗娜, 沈鑫華, 等. 社區老年輕度認知障礙人群藥源性損害的歸因特征研究. 中國全科醫學, 2020, 23(31): 4007-4012.
19.	駱佳慧, 羅園園, 方慶虹, 等. 肺癌患者認知功能的現狀及影響因素分析. 護理學報, 2023, 30(18): 1-5.
20.	馮麗娜, 賀瑾, 孟麗, 等. 老年淋巴瘤化療患者認知功能現狀及影響因素分析. 天津護理, 2020, 28(6): 639-643.
21.	Trinquinato I, Marques da Silva R, et al. Gender differences in the perception of quality of life of patients with colorectal cancer. Invest Educ Enferm, 2017, 35(3): 320-329.
22.	Wefel JS, Vardy J, Ahles T, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol, 2011, 12(7): 703-708.
23.	Zang N, Shen W, Li S, et al. Sublobar resection reduces the risk of postoperative cognitive dysfunction compared with lobectomy. Eur J Cardiothorac Surg, 2023, 64(5): ezad319.
24.	Liu S, Ni J, Yan F, et al. Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen. Front Oncol, 2022, 12: 1027515.
25.	李帥, 謝長生. 化療腦發病機制及治療的研究進展. 腫瘤學雜志, 2019, 25(4): 355-358.
26.	Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol, 2020, 324: 113118.
27.	Was H, Borkowska A, Bagues A, et al. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol, 2022, 13: 750507.
28.	Vitali M, Ripamonti CI, Roila F, et al. Cognitive impairment and chemotherapy: a brief overview. Crit Rev Oncol Hematol, 2017, 118: 7-14.
29.	Wang KY, Yang QY, Tang P, et al. Effects of ulinastatin on early postoperative cognitive function after one-lung ventilation surgery in elderly patients receiving neoadjuvant chemotherapy. Metab Brain Dis, 2017, 32(2): 427-435.
30.	Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol, 2014, 10(11): 634-642.
31.	李淑芳, 王燕, 辛士珍, 等. 化療對肺癌患者生活質量及焦慮情緒的影響及分析. 中國肺癌雜志, 2012, 15(8): 465-470.
32.	Eggen AC, Richard NM, Bosma I, et al. Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. Neurooncol Pract, 2021, 9(1): 50-58.
33.	Luo J, Liu R, Luo Y, et al. The high burden of symptoms associated with cognitive impairment in lung cancer patients: a latent class analysis. Asia Pac J Oncol Nurs, 2023, 10(4): 100200.
34.	Li N, Lu J, Xia D, et al. Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients. J Gastrointest Oncol, 2022, 13(1): 197-209.
35.	Ho MH, So TW, Fan CL, et al. Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis. Support Care Cancer, 2024, 32(4): 209.
36.	李琳. 肺癌患者治療期間癥狀群變化及影響因素研究. 廣州: 南方醫科大學, 2016.
37.	王尚虎, 閔旭紅, 宋彪, 等. 非小細胞肺癌患者認知功能和生命質量的影響因素分析. 臨床肺科雜志, 2023, 28(6): 843-847.
38.	Ospina LH, Wall M, Jarskog LF, et al. Improving cognition via exercise (ICE): study protocol for a multi-site, parallel-group, single-blind, randomized clinical trial examining the efficacy of aerobic exercise to improve neurocognition, daily functioning, and biomarkers of cognitive change in individuals with schizophrenia. J Psychiatr Brain Sci, 2019, 4: e190020.

1. Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl), 2022, 135(5): 584-590.
2. 秦娜, 馬紅霞, 靳光付, 等. 肺癌流行病學研究年度進展 2022. 中華醫學雜志, 2023, 103(14): 1068-1073.
3. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv, 2009, 3(4): 223-232.
4. Lv L, Mao S, Dong H, et al. Pathogenesis, assessments, and management of chemotherapy-related cognitive impairment (CRCI): an updated literature review. J Oncol, 2020, 2020: 3942439.
5. Wefel JS, Kesler SR, Noll KR, et al. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin, 2015, 65(2): 123-138.
6. Takemura N, Ho MH, Cheung DST, et al. Factors associated with perceived cognitive impairment in patients with advanced lung cancer: a cross-sectional analysis. Support Care Cancer, 2022, 30(11): 9607-9614.
7. Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med, 1983, 34: 35-46.
8. 黃唐, 劉丹. 肺癌患者化學治療后認知功能損傷的機制及診療進展. 華西醫學, 2021, 36(2): 255-259.
9. Simó M, Rifà-Ros X, Vaquero L, et al. Brain functional connectivity in lung cancer population: an exploratory study. Brain Imaging Behav. 2018 Apr;12(2): 369-382.
10. Simó M, Root JC, Vaquero L, et al. Cognitive and brain structural changes in a lung cancer population. J Thorac Oncol, 2015, 10(1): 38-45.
11. Országhová Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci, 2021, 8: 770413.
12. van de Kamp HJ, Molder MT, Schulkes KJG, et al. Impact of lung cancer treatment on cognitive functioning. Clin Lung Cancer, 2020, 21(2): 114-126. e3.
13. Prapa P, Papathanasiou IV, Bakalis V, et al. Quality of life and psychological distress of lung cancer patients undergoing chemotherapy. World J Oncol, 2021, 12(2/3): 61-66.
14. Papadopoulos D, Kiagia M, Charpidou A, et al. Psychological correlates of sleep quality in lung cancer patients under chemotherapy: a single-center cross-sectional study. Psychooncology, 2019, 28(9): 1879-1886.
15. Chan YN, Leak Bryant A, Conklin JL, et al. Systematic review of cognitive impairment in colorectal cancer survivors who received chemotherapy. Oncol Nurs Forum, 2021, 48(6): 634-647.
16. 周麗, 劉艷萍, 顏雯晶, 等. 肺癌化療患者的認知功能現狀及影響因素研究. 中國醫藥導報, 2020, 17(7): 86-89.
17. 李歡, 丁杏, 何惠敏, 等. 肺癌化療后神經認知功能損害的影響因素分析及其與生活質量的相關性研究. 臨床和實驗醫學雜志, 2021, 20(11): 1191-1195.
18. 王鳳, 王麗娜, 沈鑫華, 等. 社區老年輕度認知障礙人群藥源性損害的歸因特征研究. 中國全科醫學, 2020, 23(31): 4007-4012.
19. 駱佳慧, 羅園園, 方慶虹, 等. 肺癌患者認知功能的現狀及影響因素分析. 護理學報, 2023, 30(18): 1-5.
20. 馮麗娜, 賀瑾, 孟麗, 等. 老年淋巴瘤化療患者認知功能現狀及影響因素分析. 天津護理, 2020, 28(6): 639-643.
21. Trinquinato I, Marques da Silva R, et al. Gender differences in the perception of quality of life of patients with colorectal cancer. Invest Educ Enferm, 2017, 35(3): 320-329.
22. Wefel JS, Vardy J, Ahles T, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol, 2011, 12(7): 703-708.
23. Zang N, Shen W, Li S, et al. Sublobar resection reduces the risk of postoperative cognitive dysfunction compared with lobectomy. Eur J Cardiothorac Surg, 2023, 64(5): ezad319.
24. Liu S, Ni J, Yan F, et al. Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen. Front Oncol, 2022, 12: 1027515.
25. 李帥, 謝長生. 化療腦發病機制及治療的研究進展. 腫瘤學雜志, 2019, 25(4): 355-358.
26. Ongnok B, Chattipakorn N, Chattipakorn SC. Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol, 2020, 324: 113118.
27. Was H, Borkowska A, Bagues A, et al. Mechanisms of chemotherapy-induced neurotoxicity. Front Pharmacol, 2022, 13: 750507.
28. Vitali M, Ripamonti CI, Roila F, et al. Cognitive impairment and chemotherapy: a brief overview. Crit Rev Oncol Hematol, 2017, 118: 7-14.
29. Wang KY, Yang QY, Tang P, et al. Effects of ulinastatin on early postoperative cognitive function after one-lung ventilation surgery in elderly patients receiving neoadjuvant chemotherapy. Metab Brain Dis, 2017, 32(2): 427-435.
30. Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol, 2014, 10(11): 634-642.
31. 李淑芳, 王燕, 辛士珍, 等. 化療對肺癌患者生活質量及焦慮情緒的影響及分析. 中國肺癌雜志, 2012, 15(8): 465-470.
32. Eggen AC, Richard NM, Bosma I, et al. Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. Neurooncol Pract, 2021, 9(1): 50-58.
33. Luo J, Liu R, Luo Y, et al. The high burden of symptoms associated with cognitive impairment in lung cancer patients: a latent class analysis. Asia Pac J Oncol Nurs, 2023, 10(4): 100200.
34. Li N, Lu J, Xia D, et al. Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients. J Gastrointest Oncol, 2022, 13(1): 197-209.
35. Ho MH, So TW, Fan CL, et al. Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis. Support Care Cancer, 2024, 32(4): 209.
36. 李琳. 肺癌患者治療期間癥狀群變化及影響因素研究. 廣州: 南方醫科大學, 2016.
37. 王尚虎, 閔旭紅, 宋彪, 等. 非小細胞肺癌患者認知功能和生命質量的影響因素分析. 臨床肺科雜志, 2023, 28(6): 843-847.
38. Ospina LH, Wall M, Jarskog LF, et al. Improving cognition via exercise (ICE): study protocol for a multi-site, parallel-group, single-blind, randomized clinical trial examining the efficacy of aerobic exercise to improve neurocognition, daily functioning, and biomarkers of cognitive change in individuals with schizophrenia. J Psychiatr Brain Sci, 2019, 4: e190020.

West China Medical Journal

Research progress on the influencing factors of chemotherapy-related cognitive impairment in lung cancer patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content